Bioxytran, Inc. (BIXT) financial statements (2020 and earlier)

Company profile

Business Address C/O BIOXYTRAN, INC.
NEWTON, MA 02464
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17036151136
Cash and cash equivalents17036151136
Receivables50 2310  
Inventory, net of allowances, customer advances and progress billings  56  
Inventory  56  
Total current assets:22036432736
Noncurrent Assets
Property, plant and equipment  6822552107
Total noncurrent assets:  6822552107
TOTAL ASSETS:220367265256113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:7223113791202
Accounts payable70    
Accrued liabilities431925272623
Taxes payable 0    
Interest and dividends payable 421181613
Other undisclosed accounts payable and accrued liabilities22 (34)(8)50165
Debt851227105105105105
Due to related parties96111016824 
Deferred revenue and credits5   
Other undisclosed current liabilities   323128
Total current liabilities:1,019262131342251335
Noncurrent Liabilities
Other undisclosed liabilities  52   
Total liabilities:1,019262183342251335
Stockholders' equity
Stockholders' equity attributable to parent(799)(225)542(291)(195)(221)
Preferred stock  02800
Common stock86851050126
Additional paid in capital1,3567214,63813,56412,97810,858
Accumulated deficit(2,241)(383)(14,201)(13,883)(13,186)(11,086)
Total stockholders' equity:(799)(225)542(291)(195)(221)
TOTAL LIABILITIES AND EQUITY:220367265256113

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues  191246256276
Revenue, net161246256276
Cost of revenue
(Cost of Goods and Services Sold)
  (104)(96)(136)(308)
Other undisclosed gross profit     142
Gross profit:  87150120110
Operating expenses(1,631) (398)(821)(2,212)(1,390)
Operating loss:(1,631) (311)(671)(2,092)(1,281)
Nonoperating expense(227)(81) (25)(8)(66)
Interest and debt expense(42)(8)(8)(18)(8)(3)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes42(206)   3
Loss from continuing operations before equity method investments, income taxes:(1,858)(296)(318)(714)(2,108)(1,347)
Other undisclosed income from continuing operations before income taxes   188 
Loss from continuing operations before income taxes:(1,858)(296)(318)(697)(2,100)(1,347)
Income tax expense (0)    
Loss from continuing operations:(1,858)(296)(318)(697)(2,100)(1,347)
Loss from discontinued operations  (318)   
Net loss:(1,858)(296)(637)(697)(2,100)(1,347)
Other undisclosed net income attributable to parent  318   
Net loss available to common stockholders, diluted:(1,858)(296)(318)(697)(2,100)(1,347)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(1,858)(296)(637)(697)(2,100)(1,347)
Comprehensive loss, net of tax, attributable to parent:(1,858)(296)(637)(697)(2,100)(1,347)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: